RBC Europe’s Insys Therapeutics, Inc. INSY Stock Holding History

RBC Europe’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-65	Closed	-$300	–	1105
2019 Q1	$300	Hold	65	–	–	﹤0.01%	1050
2018 Q4	$228	Hold	65	–	–	﹤0.01%	1064
2018 Q3	$655	Hold	65	–	–	﹤0.01%	1085
2018 Q2	$471	Hold	65	–	–	﹤0.01%	1107
2018 Q1	$393	Hold	65	–	–	﹤0.01%	1091
2017 Q4	$625	Sell	65 -2,273	-97%	-$14.9K	﹤0.01%	1092
2017 Q3	$20.8K	Buy	+2,338	New	+$24.1K	﹤0.01%	673

Other funds holding INSY

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

RBC Europe's INSY Position: Q2 2019 in Review

RBC Europe sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 65 shares — an estimated $300 sold.

RBC Europe first reported a position in INSY in Q3 2017 and held it in 7 quarters. The position peaked at $20.8K in Q3 2017. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

RBC Europe reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
RBC Europe sold 65 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $300.
RBC Europe first reported a position in Insys Therapeutics, Inc. in Q3 2017 and held it in 7 quarters.
RBC Europe's Insys Therapeutics, Inc. position peaked at $20.8K in Q3 2017.
16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on RBC Europe's 13F filing for Q2 2019, filed 9 Nov 2023.